The Leverkusen-based conglomerate is offering investors a study in contrasts. On one side sits a freshly signed licensing agreement for hybrid wheat technology that will not generate material revenue until the 2040s. On the other, a €3 billion capital injection from Apollo Global Management and a Supreme Court ruling that has fundamentally changed the litigation calculus. The stock has responded with a 76.49 percent surge from its August 2025 low of €25.09, though the Tuesday-to-Wednesday session saw a 2.12 percent pullback to €48.12.
Hybrid wheat is the kind of long-range bet that defines Bayer’s agricultural ambitions. The company has secured an exclusive licence from French seed specialist RAGT to jointly develop hybrid wheat varieties for Europe and North America. Commercial-ready strains are expected by the early 2030s, promising a roughly 10 percent yield advantage over conventional seed. With wheat planted on more than 220 million hectares globally, the target is eye-catching: Bayer aims to generate up to €1 billion in annual revenue from hybrid wheat alone by the mid-2040s.
That patient strategy sits alongside a much more immediate financial restructuring. Apollo is injecting €3 billion of equity in exchange for a minority stake in a newly created entity that houses Bayer’s reversible long-term contraceptive business. Bayer retains operational control and the majority ownership, while the infusion shores up liquidity for upcoming bond maturities and the ongoing legal battles that have weighed on the share price for years. The structure, engineered under finance chief Judith Hartmann, signals a shift from conglomerate inertia toward targeted asset carve-outs.
The legal picture has brightened appreciably. A US Supreme Court decision on glyphosate-related claims has reduced the scope of potential damages, and the market is now watching August 19, 2026 — the scheduled settlement hearing that many hope will draw a line under the Roundup legacy. Analysts are responding. Barclays lifted its price target sharply from €50 to €60, maintaining an Overweight rating. UBS rates the stock a Buy with a €52 target. Jefferies is more cautious at €46, with a Hold. Large investors are also moving: Amundi increased its stake to 3.09 percent.
Should investors sell immediately? Or is it worth buying Bayer?
The technical backdrop reflects the rally’s intensity. At €48.12, the stock trades 17.83 percent above its 50-day moving average of €40.84 and 29.59 percent above the 200-day average. The relative strength index of 59.9 sits in neutral territory, suggesting room to run before overheating. Yet the annualised 30-day volatility of 61.75 percent underscores that this remains a high-octane name. The 52-week high of €53.86, set on July 3, is 10.66 percent above current levels.
Beyond the headline catalysts, Bayer is advancing several operational threads. ORIC Pharmaceuticals launched the global Phase 3 “Himalayas-1” trial on July 14, testing rinzimetostat in combination with Bayer’s prostate cancer drug darolutamide (Nubeqa) in about 600 patients across 25 countries. Bayer is supplying the medicine free of charge, securing a potential label expansion. Separately, the venture arm Leaps by Bayer led a financing round for Sabanto, a startup developing autonomous farming systems to combat labour shortages.
For now, the market is pricing in a genuine turnaround story — one where financial discipline, legal relief, and a willingness to unlock value through minority deals coexist with science projects that will take decades to bear fruit. Whether the Apollo transaction alone can permanently rewrite the Bayer narrative will be tested when the deal closes in the third quarter of 2026. Until then, the shares are caught between immediate tailwinds and the patience required to harvest a crop planted nearly two decades out.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from July 15 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 15.
Bayer: Buy or sell? Read more here...
